Demant A/S (OTCMKTS:WILYY) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Demant A/S Unsponsored ADR (OTCMKTS:WILYY) saw unusually-high trading volume on Thursday . 1,400 shares changed hands during trading, an increase of 165% from the previous session’s volume of 529 shares.The stock last traded at $22.50 and had previously closed at $22.58.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. UBS Group downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Zacks Research raised shares of Demant A/S to a “hold” rating in a report on Friday, June 26th. Sanford C. Bernstein lowered shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Finally, Morgan Stanley raised shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Demant A/S presently has a consensus rating of “Moderate Buy”.

Demant A/S Stock Performance

The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36. The business’s 50 day simple moving average is $20.38 and its 200-day simple moving average is $17.40.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.